Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance
Current-day drug discovery is inefficient because the focus on molecular targets misses the underlying cellular- and tissue-level dynamics of disease. AI Vivo’s Organome technology ranks drug candidates based on their phenotypic effects at the tissue level. In 2020 the company’s platform correctly predicted that dexamethasone, a commonly prescribed steroid, would save the lives of Covid-19 patients 10 weeks before researchers publicized this outcome.
Mapping the brain-body axis to achieve proper immune balance
Using AI to speed through the last mile of drug discovery
Finding precisely tuned viral vectors for gene therapy in CNS disorders
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors